118 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
22 more records may belong here and await a decision; they are not counted.
The next term ends in Mar 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
25
Ending by 2030
Mar 2027
Next term end
45
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2028 · High confidence
Also notable
Ends Jul 2030 · High confidence
Also notable
Ends Feb 2031 · High confidence
Also notable
Ends Mar 2032 · High confidence
Also notable
Ends Jun 2031 · High confidence
Also notable
Ends Aug 2034 · High confidence
Also notable
Ends Aug 2033 · High confidence
Also notable
Ends Jun 2036 · High confidence
Method of Targeting Specific Cell Populations Using Cell-Binding Agent Maytansinoid Conjugates Linked via a Non-Cleavable Linker, Said Conjugates, and Methods of Making Said Conjugates
US 8,088,387
The most cited patent in this portfolio, cited by 260 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2028.
Cross-Linkers and Their Uses
US 8,236,319
Cited by 186 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
US 8,557,966
Cited by 74 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Preparation of Maytansinoid Antibody Conjugates by a One-Step Process
US 9,428,543
Cited by 36 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Methods for Preparation of Antibody-Maytansinoid Conjugates
US 8,624,003
Cited by 47 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Monoclonal Antibodies for Detection of Folate Receptor 1
US 9,637,547
Cited by 20 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Diagnostic Assays and Kits for Detection of Folate Receptor 1
US 9,200,073
Cited by 38 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
ANTI-CD123 Antibodies and Conjugates and Derivatives Thereof
US 10,077,313
Cited by 19 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 23, 2026The maintenance fee for Cross-Linkers and Their Uses (US 9,061,995) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 1 fee due Jan 18, 2027The maintenance fee for Therapeutic Combinations Comprising ANTI-CD123 Immunoconjugates (US 11,701,428) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 3 fees due Feb 6 to 22, 2027 · next Feb 6
- 3 fees due Mar 5 to 19, 2027 · next Mar 5
- 7 fees due Apr 8 to 29, 2027 · next Apr 8
- 1 fee due May 3, 2027The maintenance fee for CD20 Antibodies and Uses Thereof (US 9,175,086) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 5 fees due Jun 1 to 5, 2027 · next Jun 1
- 2 fees due Jul 26 to 28, 2027 · next Jul 26
- 2 fees due Aug 13 to 23, 2027 · next Aug 13
- 1 fee due Sep 19, 2027The maintenance fee for Method for Increasing the Efficacy of Cancer Therapy by Administering an ANTI-FOLR1 Immunoconjugate (US 11,932,701) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
- 2 fees due Oct 2 to 7, 2027 · next Oct 2
- 2 fees due Nov 14, 2027
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 2 terms have ended since Aug 23, 2026
- Oct 30 US 10,112,925 Methods for the Preparation of Charged Crosslinkers · lapsed on the fee record
- Sep 8 US 8,383,122 Process for Preparing Purified Drug Conjugates · term ended
What they patent
The largest of its 45 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,499,893 | Oil Scavenge System Having Churning Damper for Gas Turbine Engines In force · Medium confidence | In force | Medium confidence | |
| US 7,811,572 | Process for Preparing Purified Drug Conjugates In force · Medium confidence | In force | Medium confidence | |
| US 7,989,598 | Method of Targeting Specific Cell Populations Using Cell-Binding Agent Maytansinoid Conjugates Linked via a Non-Cleavable Linker, Said Conjugates and Methods of Making Said Conjugates In force · High confidence | In force | High confidence | |
| US 8,088,387 | Method of Targeting Specific Cell Populations Using Cell-Binding Agent Maytansinoid Conjugates Linked via a Non-Cleavable Linker, Said Conjugates, and Methods of Making Said Conjugates In force · High confidence | In force | High confidence | |
| US 8,119,813 | Method for Preparing Enantiomerically Enriched N-Carboxyanhydride In force · High confidence | In force | High confidence | |
| US 8,613,930 | Cross-Linkers and Their Uses In force · High confidence | In force | High confidence | |
| US 9,061,995 | Cross-Linkers and Their Uses In force · Medium confidence | In force | Medium confidence | |
| US 9,498,541 | Cross-Linkers and Their Uses In force · Medium confidence | In force | Medium confidence | |
| US 10,494,431 | Cross-Linkers and Their Uses In force · Medium confidence | In force | Medium confidence | |
| US 11,046,762 | Cross-Linkers and Their Uses In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 118: 4 patents in force now held by others · 95 patents ended · 26 applications pending · 125 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.